US Patent

US8802689 — Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases

Method of Use · Assigned to University of California San Diego UCSD · Expires 2027-03-27 · 1y remaining

Vulnerability score 88/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of using a specific androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases.

USPTO Abstract

Described herein, inter alia, are compounds useful for the prevention or treatment of hyperproliferative diseases or disorders.

Drugs covered by this patent

Erleada (apalutamide) · Johnson & Johnson

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2237`	—	Erleada
`U-2237`	—	Erleada

Patent Metadata

Patent number: US8802689
Jurisdiction: US
Classification: Method of Use
Expires: 2027-03-27
Drug substance claim: No
Drug product claim: No
Assignee: University of California San Diego UCSD
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.